261 related articles for article (PubMed ID: 25263319)
1. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
Manasanch EE; Salem DA; Yuan CM; Tageja N; Bhutani M; Kwok M; Kazandjian D; Carter G; Steinberg SM; Zuchlinski D; Mulquin M; Calvo K; Maric I; Roschewski M; Korde N; Braylan R; Landgren O; Stetler-Stevenson M
Leuk Lymphoma; 2015 May; 56(5):1416-24. PubMed ID: 25263319
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
4. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
5. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
Yuan CM; Stetler-Stevenson M
Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
[TBL] [Abstract][Full Text] [Related]
6. [Multiple myeloma immunophenotyping: method validation].
Vergnolle I; Rieu JB; Avet-Loiseau H; Corre J; Vergez F
Ann Biol Clin (Paris); 2019 Apr; 77(2):197-217. PubMed ID: 30998199
[TBL] [Abstract][Full Text] [Related]
7. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
9. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
10. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C; Manasanch EE
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
[TBL] [Abstract][Full Text] [Related]
11. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
12. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Sanoja-Flores L; Flores-Montero J; Garcés JJ; Paiva B; Puig N; García-Mateo A; García-Sánchez O; Corral-Mateos A; Burgos L; Blanco E; Hernández-Martín J; Pontes R; Díez-Campelo M; Millacoy P; Rodríguez-Otero P; Prosper F; Merino J; Vidriales MB; García-Sanz R; Romero A; Palomera L; Ríos-Tamayo R; Pérez-Andrés M; Blanco JF; González M; van Dongen JJM; Durie B; Mateos MV; San-Miguel J; Orfao A;
Blood Cancer J; 2018 Nov; 8(12):117. PubMed ID: 30455467
[TBL] [Abstract][Full Text] [Related]
13. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
[TBL] [Abstract][Full Text] [Related]
14. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
16. Limitations of VS38c labeling in the detection of plasma cell myeloma by flow cytometry.
Czeti Á; Szalóki G; Varga G; Szita VR; Komlósi ZI; Takács F; Márk Á; Timár B; Matolcsy A; Barna G
Cytometry A; 2022 Feb; 101(2):159-166. PubMed ID: 34296508
[TBL] [Abstract][Full Text] [Related]
17. Smoldering multiple myeloma: present position and potential promises.
Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
[TBL] [Abstract][Full Text] [Related]
18. FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia.
Dorfman DM; LaPlante CD; Li B
Leuk Res; 2016 Sep; 48():40-5. PubMed ID: 27479652
[TBL] [Abstract][Full Text] [Related]
19. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
20. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
